Industrial AI for pharmaceutical manufacturing
Support SOP access, deviation and CAPA work, visual inspection and supply-chain decisions without treating an AI output as a quality approval.
Your experts define process truth. NeoBram engineers the AI. The production team validates the outcome.
Quick Answer
NeoBram engineers AI for pharmaceutical manufacturing knowledge, deviation investigation, CAPA support, visual inspection and supply-chain workflows. GxP alignment depends on intended use, risk assessment, requirements, validation evidence, access control, audit trails, change control and human approval. The pharmaceutical company's qualified quality and validation professionals remain responsible for compliance interpretation and release decisions.
Choosing a first use case
The best first project is not automatically the most advanced one. It has a named user, available data, a measurable baseline, a manageable failure mode and an owner who can accept or reject the result.
Direct answer
Start with a low-autonomy workflow where AI helps a qualified person find, compare or draft from approved evidence for example controlled SOP search or deviation precedent retrieval. Avoid beginning with automatic batch release or unsupervised quality decisions. The quality unit should define intended use, risk, records, acceptance tests and change control before development.
Decision library
These are implementation patterns, not promised outcomes. A discovery step must confirm value, feasibility and responsibility in the client's environment.
Use case 01
Use case 02
Use case 03
Use case 04
Use case 05
Use case 06
Use case 07
Integration map
A product name is an integration context, not a partnership or a guarantee that a ready-made connector exists. Access, APIs, licences, validation and security boundaries determine the final design.
QMS platforms, deviation, change-control and CAPA records through approved read-only or governed write-back interfaces.
LIMS, MES, eBR, process historians, equipment events and controlled batch context.
DMS, SOP repositories, master records, validation documents and role-based access to approved content.
SSO, role-based access, electronic records, immutable or controlled logs and review workflows.
ERP, warehouse, procurement, serialization, shipment and cold-chain data through approved interfaces.
On-premises, private-cloud or offline model serving with versioning, change control and monitored release.
Planning timeline
The clock starts only after scope, access, data, responsible owners and acceptance criteria are available.
Named workflow, owner, baseline, risks and go/no-go questions.
Data, integration, security, value and operating-readiness findings.
A bounded test on representative data with documented limitations.
One controlled workflow, integrated and evaluated with real users.
Phased scale-out, monitoring, support and change management.
Governance, delivery methods, reusable assets and team enablement.
These are planning ranges, not guaranteed delivery dates. Regulated validation, hardware procurement, sensor work, interface approvals or multi-site change management can extend them.
Governance boundary
The pharmaceutical company's quality unit, validation professionals and process owners define intended use, applicable rules, acceptance and release. NeoBram supports architecture, requirements, engineering, evaluation and evidence. The phrase GxP-aligned describes design intent; it is not a product certification or a substitute for client validation.
Review private deployment and ownershipLimitations to test
Learning resources
These references help teams understand the standards, frameworks and operating constraints that shape industrial AI projects.
U.S. Food and Drug Administration
FDA's current guidance on the scope and risk-based application of 21 CFR Part 11 to electronic records and signatures.
U.S. Food and Drug Administration
FDA guidance on a risk-based approach to software assurance in production and quality system contexts.
NIST
A voluntary framework for governing, mapping, measuring and managing AI risk across the lifecycle.
Useful tools
Calculator outputs are illustrative estimates based on your inputs and visible assumptions.
Questions buyers ask
The full answer remains in the page HTML while the visual panel is closed.
No. Compliance depends on the intended use, applicable predicate rules, system risk, records, controls, validation and operating process. NeoBram can engineer for a GxP environment and produce implementation evidence, but the pharmaceutical company's qualified quality and validation professionals approve the intended use and release.
Part 11 concerns electronic records and signatures that fall within its scope. An AI feature may affect record creation, modification, retrieval, audit trails, access or review. The project must determine which records and predicate rules apply, then use a justified, documented risk-based approach. The FDA guidance linked on this page should be reviewed with qualified counsel and validation professionals.
Validation should start from intended use and risk. Define user requirements, representative test cases, acceptance thresholds, source traceability, error handling, access, audit evidence and change control. Test the complete workflow not only model accuracy and record what the system must never do without human approval.
A system can technically integrate with approved interfaces, but write-back authority is a quality and risk decision. A safer first pattern is read-only retrieval or a clearly labelled draft that a qualified person reviews. Every write path needs identity, permissions, auditability, error handling and a validated approval workflow.
Treat model, prompt, retrieval, data and configuration changes as controlled changes. Define versioning, impact assessment, regression tests, approval, rollback and monitoring before go-live. A vendor model update should not silently change a validated workflow; pinning, evaluation gates or a local model may be needed.
Yes, when model licences and hardware support it. Offline operation can reduce external data movement, but it still needs controlled software updates, model versioning, audit logs, backup, security patching and a documented support process. The deployment boundary must be part of the validation and operating model.
The important question is coverage and quality, not only volume. A useful pilot needs representative current and historical records, stable identifiers, approved source documents, permissions and enough known questions to test retrieval and failure conditions. The quality team should help select a corpus that reflects the intended use.
We will help separate a useful first project from an expensive demonstration.
Discuss the use case